A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)

CompletadoFase 2ClinicalTrials.gov

ID: NCT02024789Tipo: INTERVENTIONALInicio: 5 de may de 2014Fin estimado: 4 de may de 2016

Traducción no disponible, mostrando original

Resumen

This multi-center, randomized, double-blind, 3-arm, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RG1662 in adults and adolescents with Down syndrome. Subjects will be randomized to receive RG1662 either at low or high dose or placebo orally twice daily for 26 weeks.

Elegibilidad

Edad mínima: 12 YearsEdad máxima: 30 YearsSexo: ALL

Criterios de inclusión

Individuals aged 12-30 years of age inclusive
Clinical diagnosis of Down syndrome (trisomy 21) confirmed by chromosomal analysis (karyotyping)
Males, or non-pregnant, non-lactating females. For females of childbearing potential, strict contraceptive prevention is required.
Body-mass Index (BMI) 18-42 and 15-30 kg/m2 inclusive for adults and adolescents respectively
Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool 2 word classes task
Subjects must have a parent, or other reliable caregiver who agrees to accompany the subject to all clinic visits, provide information about the subject as required by the protocol, and ensure compliance with the medication schedule
Study participants must have sufficient language, vision and hearing to participate in study evaluations, as judged clinically by investigator

Criterios de exclusión

Subjects with a current DSM 5 diagnosis of any primary psychiatric diagnosis (including ASD or MDD)
Subjects with a history of infantile spasms, of West syndrome, Lennox-Gastaut syndrome, Early Infantile Epileptic Encephalopathy or any treatment-refractory epilepsy associated with cognitive or developmental regression, of severe head trauma or CNS infections (e.g. meningitis)
Subjects with a known or suspected clinical seizure event of any type within 24 months prior to screening
Clinically relevant ECG abnormalities at screening or baseline; QTcF above 450 ms; personal or family history (first degree relatives) of congenital long QT syndrome
Inadequate renal or hepatic function

Intervenciones

drug

Placebo

Orally twice daily, 26 weeks

drug

RG1662

120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks

drug

RG1662

240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks

Ubicaciones

FLENI

CABA, Argentina

Instituto Neurologia Bs As

Ciudad Autonoma de Bs As, Argentina

Patrocinadores

PrincipalHoffmann-La Roche

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROL... | EligiMed